Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J  >>  Phase 4
Welcome,         Profile    Billing    Logout  

19 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Simponi (golimumab) / J&J
2014-002579-27: Pilot study on the efficacy of golimumab in normalizing the symptoms and lesions of the colon-rectum in patients with ulcerative colitis who only respond to therapy with cortisone

Ongoing
4
100
Europe
SIMPONI, NA, Solution for injection in pre-filled pen, SIMPONI
Istituto Clinico Humanitas, MSD Italia S.r.l.
active steroid-dependent ulcerative colitis, Chronic inflammation of the colon with symptoms and intestinal lesions that need continuous therapy with steroids., Diseases [C] - Digestive System Diseases [C06]
 
 
2015-002284-42: The rationale for this study is to gain insight in the extent and impact of immunogenicity of TNF inhibitors in the European daily clinical practice. Furthermore, an European wide database will give insight in factors influencing immunogenicity and treatment outcome in terms of disease activit

Ongoing
4
1650
Europe
etanercept, adalimumab, certolizumab pegol, golimumab, infliximab, Injection, Infusion, Enbrel, Humira, Cimzia, Simponi, Remicade
READE, PFIZER
rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and psoriasis., rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and psoriasis., Not possible to specify
 
 
2012-004482-40: Evaluation of a protocol for the reduction of doses in patients with rheumatoid arthritis (RA) in clinical remission in treatment with biological therapies Evaluación de un protocolo para la disminución de dosis en pacientes con Artritis Reumatoide (AR) en remisión clínica en tratamiento con terapias biológicas

Ongoing
4
28
Europe
Infliximab, Adalimumab, Etanercept, Certolizumab Pegol, Golimumab, Abatacept, Tocilizumab, HUMIRA, ENBREL, CIMZIA, SIMPONI, ORENCIA, RoActemra, HUMIRA, ENBREL, CIMZIA, SIMPONI, ORENCIA, RoActemra
FRANCISCO J. BLANCO GARCÍA, FRANCISCO J. BLANCO GARCIA
Evaluation of the clinical utility of a standardized protocol of strategies for the reduction of doses in patients with rheumatoid arthritis in clinical remission at treatment with biologic therapies Evaluación de la utilidad clínica de un protocolo estandarizado de estrategias para la disminución de dosis en pacientes con Artritis Reumatoide en remisión clínica a tratamiento con terapias biológicas
 
 
2016-003129-40: Remission after suspension of TNF alpha therapies in RA Remissione dopo terapia con farmaci Anti TNF in pazienti affetti da Artrite Reumatoide

Ongoing
4
60
Europe
HUMIRA (ADALIMUMAB), CIMZIA (Certolizumab Pegol), ENBREL (Etanercept), REMICADE (INFLIXIMAB), SIMPONI (GOLIMUMAB), [NA], [-], Solution for injection, Powder and solvent for solution for injection, Powder for solution for injection, HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 2 SIRINGHE PRERIEMPITE 0.8 ML + 2 TAMPONI IMBEVUTI DI ALCOL IN 1 BLISTER, CIMZIA - 200MG-SOLUZIONE INIETTABILE-USO SOTTOCUTANEO-SIRINGA PRERIEMPITA(VETRO) 1ML 6(3X2) SIRINGHE PRERIEMPITE+6(3X2) SALVIETTINE IMBEVUTE DI ALCOOL, ENBREL - 50 MG POLV SOLUZ INIET SOTTOC. POLV. FLAC VETRO SOLV. SIRI. VET. SOLV 1 ML (50 MG/ML) 12 FLAC+12 SIRI. PRE+12 AGHI+12 ADAT PER FLAC+24 TAMP. PRE INIEZ, REMICADE - 100 MG POLVERE PER CONCENTRATO PER INFUSIONE ENDOVENOSA 1 FLACONE VETRO 20 ML USO EV, SIMPONI - 50 MG-SOLUZIONE PER INIEZIONE IN PENNA PRERIEMPITA-USO SOTTOCUTANEO-PENNA PRERIEMPITA(VETRO) -0.5 ML 3 (3X1) PENNE PRERIEMPITE
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA, AIFA - Italian Medicines Agency
RHEUMATOID ARTHRITIS (RA) PATIENTS PAZIENTI AFFETTI DA ARTRITE REUMATOIDE (AR), RHEUMATOID ARTHRITIS (RA) PATIENTS PAZIENTI AFFETTI DA ARTRITE REUMATOIDE (AR), Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2017-001374-42: Measuring levels of golimumab to improve the understanding of differences in its effectiveness amongst patients with ulcerative colitis

Not yet recruiting
4
112
Europe
Golimumab, Solution for injection in pre-filled pen, Simponi
Guy's and St Thomas' NHS Foundation Trust, Merck Sharp & Dohme
Ulcerative Colitis (UC), Ulcerative Colitis (UC), Diseases [C] - Digestive System Diseases [C06]
 
 
2017-001970-41: Dose reduction and withdrawal of biological therapy in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: Protocol for a 18 months multi-centre trial

Ongoing
4
180
Europe
Abatacept, Adalimumab, Certolizumab pegol, Etanercept, Golimumab, Infliximab, Tocilizumab, L04AA24, L04AB04, L04AB05, L04AB01, L04AB06, L04AB02, L04AC07, Concentrate for solution for injection, Concentrate and solvent for solution for infusion, Concentrate and solvent for solution for injection, Concentrate and solvent for suspension for injection, Orencia, Humira, Cimzia, Enbrel, Benepali, Simponi, Remsima, Remicade, RoActemra, Inflectra, Imraldi, Amgevita
MD, PhD Salome Kristensen, The Danish Regions (Regionernes Medicinpulje), The Department of Rheumatology at Aalborg University Hospital, Health Science Research Fund of the Region of Northern Jutland
Rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis, Rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis (arthritis of the spine), Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2018-003432-72: Dose reduction and withdrawal of TNF inhibitors in patients with Psoriatic Arthritis and Axial Spondyloarthritis Afbouwen en stoppen van TNF remmers bij patiënten met Artritis Psoriatica en Axiale Spondylartritis.

Ongoing
4
234
Europe
Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab, Solution for injection/infusion, Tumor Necrosis Factor alpha (TNF-a) Inhibitors: Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab
Sint Maartenskliniek, Sint Maartenskliniek
Adults diagnosed with Psoriatic Arthritis en Axial Spondyloarthritis. Volwassenen gediagnosticeerd met artritis psoriatica en axiale spondylartritis., Psoriatic arthritis and Axial Spondyloarthritis Artritis psoriatica en axiale spondylartritis, Diseases [C] - Immune System Diseases [C20]
 
 
2018-002925-47: prediction of response to therapy in inflammatory bowel disease Predicción de respuesta al tratamiento en la enfermedad inflamatoria intestinal

Not yet recruiting
4
180
Europe
Injection, Infusion, Adalimumab, Infliximab, Golimumab, Ustekinumab, Vedolizumab
Fundación de Investigación Biomédica del Hospital Universitario de La Princesa, Instituto de Salud Carlos III
Inflammatory bowel disease Enfermedad inflamatoria intestinal, Corhn´s disease and ulcerative colitis Enfermedad de Crohn y colitis ulcerosa, Diseases [C] - Digestive System Diseases [C06]
 
 
2016-000152-96: Intensive Treatment to Reach the target with Golimumab in ulcErative coliTis – In-TARGET Traitement intensif par golimumab pour atteindre la cible thérapeutique dans la rectocolite hémorragique (RCH) - In-TARGET

Not yet recruiting
4
200
Europe
Solution for injection, SIMPONI 50 mg, SIMPONI 100 mg
GETAID, Pharmaceutical company
Moderate to severe ulcerative colitis Rectocolite hémorragique modérée à sévère, Moderate to severe ulcerative colitis who failed corticosteroids and immunosuppressive therapy, or are intolerant to immunosuppressors. Rectocolite hémorragique (RCH) modérée à grave pour laquelle un traitement avec des anticorps dirigés contre le facteur de nécrose tumorale (TNF) est jugé nécessaire., Diseases [C] - Digestive System Diseases [C06]
 
 
2019-003987-37: Comparison of Two Different Golimumab Dosing Regimens for Ulcerative Colitis Primerjava dveh različnih shem odmerjanja golimumaba pri ulceroznem kolitisu

Not yet recruiting
4
30
Europe
Simponi, CNTO-148, Solution for injection in pre-filled pen, Simponi
University Medical Centre Ljubljana, Department of gastroenterology, University Medical Centre Ljubljana, Department of gastroenterology
Ulcerative colitis Ulcerozni kolitis, Inflammatory bowel disease - ulcerative colitis Kronična vnetna črevesna bolezen - ulcerozni kolitis., Diseases [C] - Digestive System Diseases [C06]
 
 
2020-004391-18: IMPACT OF ANTI-TNF, VEDOLIZUMAB AND TOFACITINIB ON AORTIC STIFFNESS, CAROTID INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK OF PATIENTS WITH ULCERATIVE COLITIS Impact des anti-TNF, du vedolizumab et du tofacitinib sur la rigidité aortique, l'épaisseur de l'intima-média carotidienne et le risque cardiovasculaire des patients atteints de rectocolite hémorragique

Not yet recruiting
4
100
Europe
Inflectra 100 mg, AMGEVITA, Simponi, Entyvio 300 mg, XELJANZ, Powder and solvent for concentrate for solution for infusion, Solution and suspension for suspension for injection in pre-filled syringe, Solution for injection in pre-filled pen, Tablet, Inflectra 100 mg, AMGEVITA, Simponi, Entyvio 300 mg, XELJANZ
CHU Amiens-Picardie, Pfizer
ulcerative colitis rectocolite hémorragique, ulcerative colitis rectocolite hémorragique, Diseases [C] - Digestive System Diseases [C06]
 
 
2021-002211-65: EFFECT OF TOFACITINIB ON COAGULATION EFECTO DE TOFACITINIB SOBRE LA COAGULACIÓN

Ongoing
4
60
Europe
Injection, Infusion, Pastille, Adalimumab, Infliximab, Golimumab, Tofacitinib
Fundación Española de Gastroenterología, pfizer
ulcerative colitis colitis ulcerosa, ulcerative colitis colitis ulcerosa, Body processes [G] - Biological Phenomena [G16]
 
 
TARGET, NCT02425865: Intensive Treatment to Reach the Target With Golimumab in ulcErative coliTis - In-

Completed
4
202
Europe
GOLIMUMAB
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
ULCERATIVE COLITIS
10/21
01/23
NCT04156984: Comparison of Two Different Golimumab Dosing Regimens for Ulcerative Colitis

Completed
4
27
Europe
Golimumab Prefilled Syringe
David Drobne
Ulcerative Colitis
06/24
06/24
NCT05313620: Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events

Recruiting
4
30
Europe
Tofacitinib, Infliximab Adalimumab y Golimumab
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Ulcerative Colitis, Thromboembolism
10/24
10/24
BioIBD, NCT03885713: Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease

Recruiting
4
180
Europe
Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
12/24
12/24
BIOTAPE, NCT05115903: Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis

Active, not recruiting
4
15
Canada
Tapered doses of TNFi, etanercept 50 mg every 10 days (75% of baseline dose), 14 days (50%), 30 days (25%), adalimumab 40 mg every 3 weeks (75%), 4 weeks (50%), 16 weeks (25%), certolizumab pegol 200 mg 3 weeks (75%), 4 weeks (50%), 16 weeks (25%), golimumab 50 mg every 6 weeks (75%), 8 weeks (50%), 16 weeks (25%), infliximab 5 mg/kg every 8 weeks (75%), 12 weeks (50%), 16 weeks (25%), Standard dose of TNFi, etanercept 50 mg every 7 days, adalimumab 40 mg every 2 weeks, certolizumab pegol 200 mg every 2 weeks, golimumab 50 mg every 4 weeks, infliximab 5 mg/kg every 6 weeks
University Health Network, Toronto
Axial Spondyloarthritis
07/24
08/24
COVER, NCT05080218: COVID-19 VaccinE Response in Rheumatology Patients

Recruiting
4
1000
US
Upadacitinib, Rinvoq, Abatacept, Orencia SQ, Secukinumab, Cosentyx, Tofacitinib, Xeljanz, TNF Inhibitor, Etanercept, Certolizumab, Golimumab SQ, Adalimumab, Canakinumab Injection, Ilaris, Baricitinib, Olumiant, Ixekizumab, Taltz
Jeffrey Curtis, University of Alabama at Birmingham, University of Nebraska, University of Pennsylvania, AbbVie, Bristol-Myers Squibb, Novartis, Eli Lilly and Company, Pfizer, Illumination Health
Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
02/24
09/24
ChiCTR2000033582: Study of Efficacy and safety with golimumab in the treatment of children’s rheumatic diseases

Not yet recruiting
4
300
 
golimumab IH ;Oral traditional medicine
Guangzhou Women and Children's Medical Center; Guangzhou Women and Children's Medical Center, Guangzhou Women and Children’s Medical Center,Internal Medicine Fund Project
Rheumatic diseases in children
 
 

Download Options